TRPM8 and cancer: Plasma concentrations of rapamycin in patients on systemic drug regimens following organ transplantation or for the treatment of lymphangioleiomyomatosis or cancer rarely exceed 100 nM (Jimeno et al., 2008; Trepanier et al., 1998), rendering it unlikely that substantial rapamycin-induced TRPM8 activation would occur in these subjects.